[144] Rocket Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Rocket Pharmaceuticals, Inc. (RCKT) – Form 144 filing discloses that insider Aaron Ondrey intends to sell 1,477 common shares through Fidelity Brokerage Services on 07 July 2025. The planned transaction is valued at approximately $4,256.42, based on the market price at the time of filing. The shares were acquired via restricted-stock vesting on 01 July 2025 and constitute less than 0.002% of the 107.7 million shares outstanding. The insider previously sold 7,489 shares on 04 Apr 2025 for $39,646.77.

The filing is a routine notification under Rule 144 and does not, by itself, indicate any change to Rocket Pharmaceuticals’ fundamentals. The modest size of the transaction suggests minimal dilution or ownership impact for existing shareholders.

Positive

• None.

Negative

• Insider selling activity (1,477 shares now; 7,489 shares in April) may be viewed cautiously by some investors, although the volume is immaterial.

Insights

Securities Analyst

TL;DR: Small insider sale (1,477 shares) is routine and immaterial; neutral impact on valuation.

The sale represents an insignificant fraction of RCKT’s float and follows a prior 7,489-share disposal in April. The shares stem from recent RSU vesting, typical for employee compensation. With aggregate value below $50k, liquidity and ownership structure remain largely unchanged. No additional information on financial performance or strategic direction is provided, so the filing is best viewed as administrative. Investors should monitor future insider activity for patterns but need not adjust models on this disclosure alone.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1477	4256.42	107737919	07/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/01/2025	Restricted Stock Vesting	Issuer			1477	07/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Aaron Ondrey 9 Cedarbrook Drive Cranbury NJ 08512	Common	04/04/2025	7489	39646.77

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Rocket Pharmaceuticals (RCKT) shares are being sold under this Form 144?

1,477 common shares are planned for sale.

What is the estimated market value of the planned sale?

Approximately $4,256.42 based on the filing.

When is the insider sale expected to occur?

On or about 07 July 2025.

What proportion of RCKT’s outstanding shares does the sale represent?

Less than 0.002% of the 107,737,919 shares outstanding.

Were there recent insider sales prior to this notice?

Yes. 7,489 shares were sold on 04 Apr 2025 for $39,646.77.